PD L 506 for Stereotactic Interstitial Photodynamic Therapy of Newly Diagnosed Supratentorial IDH Wild-type Glioblastoma
Evaluation of the Feasibility of PD L 506 for Stereotactic Interstitial Photodynamic Therapy (iPDT) in Adult Patients With Newly Diagnosed Supratentorial IDH Wild-type Glioblastoma
Sponsor: photonamic GmbH & Co. KG
Listed as NCT03897491, this PHASE2 trial focuses on Glioblastoma and remains ongoing. Sponsored by photonamic GmbH & Co. KG, it has been updated 14 times since 2021, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
14 versions recorded-
Sep 2025 — Present [monthly]
Active Not Recruiting PHASE2
-
Jun 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Sep 2024 — Jun 2025 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Dec 2023 — Jul 2024 [monthly]
Recruiting PHASE2
▶ Show 9 earlier versions
-
Sep 2022 — Dec 2023 [monthly]
Recruiting PHASE2
-
Mar 2022 — Sep 2022 [monthly]
Recruiting PHASE2
-
Oct 2021 — Mar 2022 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Apr 2021 — Oct 2021 [monthly]
Not Yet Recruiting PHASE2
-
Jan 2021 — Apr 2021 [monthly]
Not Yet Recruiting PHASE2
-
Sep 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE2
-
Feb 2020 — Sep 2020 [monthly]
Not Yet Recruiting PHASE2
-
Sep 2019 — Feb 2020 [monthly]
Not Yet Recruiting PHASE2
-
May 2019 — Sep 2019 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- photonamic GmbH & Co. KG
For direct contact, visit the study record on ClinicalTrials.gov .